The Eye Care Institute is a research study site offering trials of new treatments for dry eye disease, presbyopia (age-related loss of near vision), glaucoma, conjunctivitis (pink-eye), post-surgical inflammation, LASIK vision correction, and many other ocular conditions.
We regularly recruit patients (study subjects) to enroll in trials sponsored by pharmaceutical companies, surgical and medical equipment firms, and others developing new treatment options. These trials help to confirm the effectiveness of new pharmaceuticals, surgical implants, diagnostic medical devices and other therapies. All of these clinical trials are done with the ultimate goal of getting the medication, implant, device or other treatment to become approved by the United States Food and Drug Administration (FDA).
At The Eye Care Institute, we take your health, wellness and vision very seriously. That is why we only participate in Phase II, III, and IV trials, as well as post-marketing studies. Specifically, only after the investigational device, implant or drug has been proven not to be harmful, we then participate in clinical trials to determine how successfully the therapy being tested works, and for how long.
Participation in clinical trials offers patients access to new medications, diagnostic treatments or surgical implants (all at no cost) which may improve the quality of your vision or improve your comfort. Further, your participation may have a positive impact on the lives of patients in the future. Many studies offer compensation for your travel expense and time.
If you want to be included in a clinical study, please use the form below to be considered for treatment of these or other conditions:
- Dry Eye Disease
- LASIK Vision Correction
Or, call one of our clinical research coordinators at 502-589-1500 to find out if participation in a clinical trial may be right for you.
Here is a listing of many of the significant clinical trials in which we have participated (scroll the list to view all):
|Glaucoma||A comparison of Investigational Product to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension.||Enrolling Fall 2017|
|Chalazion||A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of an Investigational Product Transdermal System (TDS) as Compared to Placebo TDS in Patients with a Chalazion.||July 2017- Present|
|A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Investigational Ophthalmic Solution in Subjects with Dry Eye Associated with Primary Sjögren’s Syndrome.||July 2017- Present|
|Neurotrophic Keratopathy||A Phase 3, Multi-center, Randomized, Double-masked, Placebo-controlled Clinical Study to Assess the Safety and Efficiency of an Investigational Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy.||May 2017- Present|
|Adenoviral Conjunctivitis||A Phase 3, Multi-center, Randomized, Double-Masked Study to evaluate the Clinical Efficacy and Safety of Investigational Ophthalmic Suspension Compared to Placebo in the Treatment of Adenoviral Conjunctivitis.||May 2017- Present|
|Bacterial Conjunctivitis||A Phase 3, Multi-center, Randomized, Double-Masked Study to evaluate the Clinical Efficacy and Safety of Investigational Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis.||May 2017- Present|
|Dry Eye Disease||A Multi-Center, Randomized, Double-Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of Investigational Ophthalmic Solution for the Treatment of Dry Eye in a Controlled Adverse Environment (CAE).||January 2017- Present|
|Dry Eye Disease||A Phase 3, Double-Masked, Randomized, Controlled Study of Investigational Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease.||July 2016- Present|
|Presbyopia||A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy and Pharmacokinetics of a Fixed Combination of Investigational Products (Ophthalmic Solution) in Patients with Presbyopia.||June 2016- Present|
|Presbyopia||A Prospective, Multicenter Clinical Trial Of An Investigational Implant System For Improvement Of Near Visual Acuity In Presbyopic Patients||November 2014- Present|
|Corneal Wound||A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of Investigational Ophthalmic Solution Compared with Placebo to Assess Safety and Efficacy of Two Dose Concentrations of Investigational Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients with Moderate to Severe Corneal Epithelial Disorders.||October 2016- April 2017|
|Glaucoma||A Phase 1-2 Multi-center, Randomized, Controlled, Dosing-Finding Study Designed to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the Investigational Sustained Release Subconjunctival Insert in Subjects with Open-Angle glaucoma or Ocular Hypertension.||September 2016- April 2017|
|Dry Eye Disease||Multicenter, Randomized, Controlled, Single-Masked, Cross-Over Clinical Trial to Evaluate the Reduction in the Exacerbation of Dry Eye Symptoms Upon Exposure to a Controlled Adverse Environment (CAE) with Treatment by an Investigational Device.||September 2016- November 2016|
|Cataract Surgery||A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Investigational Ophthalmic Suspension in Subjects with Postsurgical Inflammation and Pain.||June 2016- April 2017|
|Dry Eye Disease||A Safety and Efficacy Study of Investigational Ophthalmic Solution for the Treatment of Dry Eye Disease.||January 2016- September 2016|
|Glaucoma/ Ocular Hypertension||A Phase 3 Prospective, Double-Masked, Randomized, Multi-Center, Active-Controlled, Parallel-Group 12 Month Study Assessing The Safety And Ocular Hypertensive Efficacy of Investigative Ophthalmic Solution Compared To Other Ophthalmic Solution, 0.02% And Ophthalmic Solution, 0.005% In Subjects With Elevated Intraocular Pressure.||September 2015- July 2017|
|Dry Eye Disease||A Phase 3 Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of Investigational Topical Ophthalmic Solution versus Vehicle Control in Subjects with Moderate to Severe Dry Eye Disease (DED).||March 2014- November 2015|
|Glaucoma and Cataract||The Safety and Effectiveness of an Investigational Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial.||February 2014- Present|
|Cataract Surgery||A Phase 3, Multi-Center, Double Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Investigative Ophthalmic Gel, 0.38% (BID and TID) versus Vehicle Gel for the treatment of Ocular Inflammation and Pain Following Cataract Surgery.||February 2014- August 2014|
|Dry Eye Disease||A Randomized, Multi-Center, Parallel-Group Safety and Efficacy Study of Investigational Ophthalmic Gel 0.5% and Ophthalmic Solution 0.05% for 12 Weeks in Subjects with Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED).||May 2013 - June 2014|
|Dry Eye Disease||A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Investigational Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Currently Using Artificial Tears. December 2012 - October 2013||December 2012- October 2013|
|Dry Eye Disease||A Dose Ranging Study to Evaluate Safety and Efficacy of Investigational Ophthalmic Solution in Dry Eye Disease.||December 2011- December 2012|
|Cataract Surgery||Efficacy of Investigational Ophthalmic Solution in Patients Undergoing Cataract Surgery. May 2011 - December 2011||May 2011- December 2011|
|Dry Eye Disease||Efficacy and Safety Study of Investigational Ophthalmic Solution 1% / 0.2% Fixed Combination TID vs. Other Investigational products, TID.||March 2011- March 2012|
|Cataract Surgery||Efficacy and Safety of Investigational Ophthalmic Solution in Cataract Surgery.||June 2008- November 2008|
|Dry Eye Disease||Study of Investigational Ophthalmic Solution in the Treatment of Dry Eye Syndrome. October 22, 2007 to June 29, 2011||October 2007- June 2011|
|Glaucoma||A Study of Safety and IOP-Lowering Efficacy of Investigational Ophthalmic Solution in Patients with Open-Angle Glaucoma.||March 2007- August 2007|
|Glaucoma||Investigational Ophthalmic Solution as First Line Therapy to Reduce Intraocular Pressure in Patients With Untreated Open Angle Glaucoma (OAG) or Ocular Hypertension (OH). May 2006 to August 2007||May 2006- August 2007|
|Glaucoma and Cataract Surgery||A Study of an Investigational Device (Stent) in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.||June 2005- March 2010|
|Presbyopia||A Prospective, Multicenter Clinical Trial of An Investigational Scleral Implant For the Improvement of near Visual Acuity in Presbyopic Patients.||December 2003- March 2015|
|Cataract Surgery||Efficacy and Safety of An Investigational Topical Ophthalmic Solution, 0.09% vs. Placebo for Treatment of Ocular Inflammation Following Cataract Surgery.||May 2003- August 2004|
|Corneal Erosion||Investigational Topical Ophthalmic Solution in Treating Recurrent Corneal Erosion. September 2001 to August 2004||September 2001- August 2004|
|Dry Eye Disease||Effects of Investigational Ophthalmic Solution on Aqueous Dynamics. January 2001||January 2001|
|Glaucoma/ Ocular Hypertension||A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Investigational Products with The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension. August 1997 to June 1999||August 1997- June 1999|
Other Clinical Trial Involvement
|Multiple Contracts for Ophthalmic Exams to Be Coordinated as Needed with Clinical Trials Being Conducted at Norton Healthcare. Sponsored by Norton Cancer Institute.||2014- Present|
Study sponsors, pharmaceutical companies, biotechnology firms and CRO’s: If you wish to consider using our site, please contact us at email@example.com.
The Eye Care Institute is a member of the Society for Clinical Research Sites.